Sciences presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial, which is studying ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Heal ...

At the start of this year, I observed that shares of Gilead Sciences, Inc. (NASDAQ:GILD) saw a downward re-rating after the ...

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on GILD stock, giving a Buy rating yesterday. Daina ...

BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...

There are a whole host of reasons why Ireland has historically succeeded in attracting more than 90 biopharma companies to ...

Gilead Sciences (GILD) closed the latest trading day at $87.23, indicating a -1.05% change from the previous session's end. This move lagged the S&P 500's daily loss of 0.92%. Meanwhile ...

Cork-based SUAS Aerospace has announced a partnership with Netherlands-based T-Minus Engineering for Ireland's first commercial rocket launch next year. The Pathfinder mission is due to blast off ...

Gardaí are investigating a tragic road crash in which a young man died after the vehicle he was driving left the road in West Cork on Monday, October 21. The man, in his 20s, was driving a car ...